Metabolic dysfunction-associated steatotic liver disease — MASLD, the condition formerly called NAFLD — is one of the most common comorbidities in patients seeking weight loss treatment. Many patients discover they have it only when a prescriber orders baseline labs. Here's what the accumulating evidence means for you.
Key Takeaways
- MASLD is extremely common in patients with obesity and is frequently silent until labs reveal elevated liver enzymes.
- Weight loss of 7–10% is the established threshold associated with improvement in liver fat and inflammation.
- GLP-1 therapy reliably produces weight loss in that range, and trial evidence through mid-2026 supports meaningful hepatic benefit, particularly with semaglutide in MASH.
- Elevated baseline ALT/AST is usually a reason to treat, not a contraindication — but it requires monitoring.
What MASLD Actually Is
MASLD describes fat accumulation in the liver driven by metabolic dysfunction rather than alcohol. Its aggressive form — MASH, with active inflammation — can progress to fibrosis and cirrhosis. The disease is usually silent for years. Mildly elevated ALT on a routine panel is often the only early signal, which is exactly why legitimate GLP-1 prescribers order liver enzymes at intake.
Why Weight Loss Is the Primary Therapy
Hepatology guidance has been consistent for years: sustained weight loss of roughly 7–10% of body weight is associated with reduced liver fat, and greater losses with improvement in inflammation and even fibrosis. The historical problem was that few interventions reliably produced 10% loss. GLP-1 therapy changed that arithmetic — average losses in semaglutide and tirzepatide trials comfortably span the hepatic-benefit threshold.
What the Trial Evidence Shows
Semaglutide has published trial data in biopsy-confirmed MASH showing resolution of steatohepatitis in a substantially higher proportion of treated patients versus placebo. Tirzepatide has shown similar directionally strong results in MASH populations. The consistent pattern through mid-2026: GLP-1-class therapy improves the metabolic drivers of the disease, and liver outcomes follow the weight and insulin-sensitivity improvements.
What This Means at Your Intake
If your baseline labs show ALT or AST elevation, expect your prescriber to: repeat the panel at 3–6 months, possibly calculate a FIB-4 score (a simple fibrosis estimate from age, AST, ALT, and platelets), and refer to hepatology only if fibrosis markers are elevated. Mild enzyme elevation with a MASLD picture is generally an argument for treating the underlying metabolic disease.
Choosing a Provider That Does Real Lab Review
This is an area where provider quality genuinely matters. Programs that require or review baseline labs can catch MASLD and track your hepatic response; questionnaire-only mills cannot. Among the programs we track, these offer physician-supervised care at accessible prices:
Embody
Injectable semaglutide — $149 first month
Physician-supervised injectable semaglutide program with straightforward flat monthly pricing after the intro month.
Compounded medications are not FDA-approved.
Visit Embody Paid linkFound Health
Dissolvable tablets — sema $189/4wk
Dissolvable compounded semaglutide tablets with a structured behavioral program alongside the medication.
Compounded medications are not FDA-approved.
Visit Found Health Paid linkIf you already know you have fatty liver, don't let it scare you away from treatment — bring it to the consultation. In 2026, it's one of the strongest clinical arguments for treating your weight medically rather than waiting.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.